Mogelijk gemaakt door Google TranslateTranslate
Oorspronkelijke tekst
Deze vertaling beoordelen
Je feedback wordt gebruikt om Google Translate te verbeteren
Latest Press Releases
View all
TimeHeadline
9h agoDelivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
10h agoRefers to Item 7 on the agenda: Report on the audit of the consolidated financial statements of Grupa Kęty SA
12h agoThe 4th BOCHK Science and Technology Innovation Prize Award Ceremony Concludes with Great Success
20h agoBuffalo Potash Files Annual Information Form and New Technical Report
21h agoIonik Announces 30-Day Extension of Senior Debt Facility
Hls Therapeutics, Inc. logo

Hls Therapeutics, Inc.

About

4.64CAD+0.05 +1.09%
Closed • Updated at 23:37 GMT+00:00
Market Cap$105.28M
Volume10.1K
Beta0.60
RSI52.74
Gross Margin41.97%
Health TechnologyPharmaceuticals: Major

Hls Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.

Latest News

May 15 2026
HLS Therapeutics Announces Q1 2026 Financial Results
May 1 2026
HLS Therapeutics to Host Q1 2026 Financial Results Conference Call
Apr 14 2026
HLS Therapeutics to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
Mar 12 2026
HLS Therapeutics Announces Fiscal 2025 Financial Results
Mar 5 2026
HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease

Community Chat

Ask AI

Try asking
6ix6ixAIEvents